Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Phase

Division (Location)

Study ID

NCT#

Brief Description
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.